Atara Biotherapeutics, Inc. 8-K

What Happened
Atara Biotherapeutics (ATRA) filed an 8-K on March 16, 2026 reporting that it announced financial results for the fourth quarter and full year ended December 31, 2025. The company furnished a press release titled “Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress” as Exhibit 99.1 to the filing. The report was signed by Yanina Grant-Huerta, Chief Accounting Officer, on behalf of the company.

Key Details

• Announcement date: March 16, 2026.
• Period covered: Quarter and year ended December 31, 2025.
• Press release furnished as Exhibit 99.1 (titled as above).
• 8-K executed and certified by Yanina Grant-Huerta, Chief Accounting Officer.

Why It Matters
This 8-K signals that Atara has released its latest earnings and operational update; investors should read the March 16 press release (Exhibit 99.1) to see key metrics such as revenue, net income/loss, cash position, and any operational or program milestones. Those figures and commentary will be important for assessing the company’s near-term financial health and progress on development programs.